Cargando…

Quinazoline Based HDAC Dual Inhibitors as Potential Anti-Cancer Agents

Cancer is the most devastating disease and second leading cause of death around the world. Despite scientific advancements in the diagnosis and treatment of cancer which can include targeted therapy, chemotherapy, endocrine therapy, immunotherapy, radiotherapy and surgery in some cases, cancer cells...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dhuguru, Jyothi, Ghoneim, Ola A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9000668/ https://www.ncbi.nlm.nih.gov/pubmed/35408693 http://dx.doi.org/10.3390/molecules27072294

Ejemplares similares

Role of Indole Scaffolds as Pharmacophores in the Development of Anti-Lung Cancer Agents
por: Dhuguru, Jyothi, et al.
Publicado: (2020)

Synthesis of potent and selective HDAC6 inhibitors led to unexpected opening of a quinazoline ring
por: Moi, Davide, et al.
Publicado: (2022)

Hybrid topoisomerase I and HDAC inhibitors as dual action anticancer agents
por: Cincinelli, Raffaella, et al.
Publicado: (2018)

FDA-Approved Oximes and Their Significance in Medicinal Chemistry
por: Dhuguru, Jyothi, et al.
Publicado: (2022)

Discovery and biological evaluation of novel CARM1/HDAC2 dual-targeting inhibitors with anti-prostate cancer agents
por: Liang, Sudong, et al.
Publicado: (2023)

Benzo[g]quinazolin-based scaffold derivatives as dual EGFR/HER2 inhibitors
por: Ghorab, Mostafa M., et al.
Publicado: (2017)

Quinazoline Derivatives as Potential Therapeutic Agents in Urinary Bladder Cancer Therapy
por: Wdowiak, Paulina, et al.
Publicado: (2021)

Single Inhibitors versus Dual Inhibitors: Role of HDAC in Cancer
por: Roy, Rubi, et al.
Publicado: (2023)

Defining NAD(P)(H) Catabolism
por: Dhuguru, Jyothi, et al.
Publicado: (2023)

Novel Single Inhibitor of HDAC6/8 and Dual Inhibitor of PI3K/HDAC6 as Potential Alternative Treatments for Prostate Cancer
por: Guerra, Fabiana Sélos, et al.
Publicado: (2021)

HDAC and HDAC Inhibitor: From Cancer to Cardiovascular Diseases
por: Yoon, Somy, et al.
Publicado: (2016)

Novel quinazoline and acetamide derivatives as safe anti-ulcerogenic agent and anti-ulcerative colitis activity
por: Alasmary, Fatmah A.S., et al.
Publicado: (2018)

Exploration of thiaheterocyclic hHDAC6 inhibitors as potential antiplasmodial agents
por: Vreese, Rob De, et al.
Publicado: (2017)

MSCs as Tumor-Specific Vectors for the Delivery of Anticancer Agents—A Potential Therapeutic Strategy in Cancer Diseases: Perspectives for Quinazoline Derivatives
por: Szewc, Monika, et al.
Publicado: (2022)

Design, synthesis and biological evaluation of VEGFR-2/HDAC dual inhibitors as multitargeted antitumor agents based on fruquintinib and vorinostat
por: Gao, Yali, et al.
Publicado: (2023)

Design, Synthesis, and Biological Evaluation of Novel Quinazolin-4(3H)-One-Based Histone Deacetylase 6 (HDAC6) Inhibitors for Anticancer Activity
por: Khetmalis, Yogesh Mahadu, et al.
Publicado: (2023)

Novel dual LSD1/HDAC6 inhibitor for the treatment of cancer
por: Gajendran, Chandru, et al.
Publicado: (2023)

Guanidine Derivatives of Quinazoline-2,4(1H,3H)-Dione as NHE-1 Inhibitors and Anti-Inflammatory Agents
por: Spasov, Alexander, et al.
Publicado: (2022)

Deep eutectic solvent for an expeditious sono-synthesis of novel series of bis-quinazolin-4-one derivatives as potential anti-cancer agents
por: Ahmed Arafa, Wael Abdelgayed
Publicado: (2019)

Involvement of HDAC1 and HDAC3 in the Pathology of Polyglutamine Disorders: Therapeutic Implications for Selective HDAC1/HDAC3 Inhibitors
por: Thomas, Elizabeth A.
Publicado: (2014)

Some novel hybrid quinazoline-based heterocycles as potent cytotoxic agents
por: Malekzadeh, Mahla, et al.
Publicado: (2021)

HDAC inhibitors with potential to overcome drug resistance in castration-resistant prostate cancer
por: Biersack, Bernhard, et al.
Publicado: (2022)

Discovery of Novel Quinazoline Derivatives as Potent Antitumor Agents
por: Niu, Zhenxi, et al.
Publicado: (2022)

Synthesis of chalcone incorporated quinazoline derivatives as anticancer agents
por: Madhavi, Sapavat, et al.
Publicado: (2017)

Metabolism, HDACs, and HDAC Inhibitors: A Systems Biology Perspective
por: King, Jacob, et al.
Publicado: (2021)

HDAC Inhibitors: Therapeutic Potential in Fibrosis-Associated Human Diseases
por: Yoon, Somy, et al.
Publicado: (2019)

Structure–Activity Relationship Studies Based on Quinazoline Derivatives as EGFR Kinase Inhibitors (2017–Present)
por: Șandor, Alexandru, et al.
Publicado: (2023)

Novel HDAC/Tubulin Dual Inhibitor: Design, Synthesis and Docking Studies of α-Phthalimido-Chalcone Hybrids as Potential Anticancer Agents with Apoptosis-Inducing Activity
por: Mourad, Ahmed A E, et al.
Publicado: (2020)

Natural chalcones as dual inhibitors of HDACs and NF-κB
por: ORLIKOVA, B., et al.
Publicado: (2012)

Hydroxamic Acids Immobilized on Resins (HAIRs): Synthesis of Dual‐Targeting HDAC Inhibitors and HDAC Degraders (PROTACs)
por: Sinatra, Laura, et al.
Publicado: (2020)

Immune modulation underpins the anti‐cancer activity of HDAC inhibitors
por: Blaszczak, Wiktoria, et al.
Publicado: (2021)

Design and Discovery of Quinazoline- and Thiourea-Containing Sorafenib Analogs as EGFR and VEGFR-2 Dual TK Inhibitors
por: Sun, Shaofeng, et al.
Publicado: (2017)

Quinazoline derivatives: synthesis and bioactivities
por: Wang, Dan, et al.
Publicado: (2013)

Emission Tuning of Fluorescent Kinase Inhibitors: Conjugation Length and Substituent Effects
por: Dhuguru, Jyothi, et al.
Publicado: (2014)

Quinazolin-4(3H)-one based potential multiple tyrosine kinase inhibitors with excellent cytotoxicity
por: Mirgany, Tebyan O., et al.
Publicado: (2021)

Aaptamine – a dual acetyl – and butyrylcholinesterase inhibitor as potential anti-Alzheimer’s disease agent
por: Miao, Shuang, et al.
Publicado: (2022)

Dual-Mode HDAC Prodrug for Covalent Modification and Subsequent Inhibitor Release
por: Daniel, Kevin B., et al.
Publicado: (2015)

HDAC Inhibitors Exert Anti-Myeloma Effects through Multiple Modes of Action
por: Imai, Yoichi, et al.
Publicado: (2019)

Quinazoline analogues as cytotoxic agents; QSAR, docking, and in silico studies
por: Emami, Leila, et al.
Publicado: (2021)

Potential repurposing of the HDAC inhibitor valproic acid for patients with COVID-19
por: Pitt, Bertram, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ud47o9bku81rkoced7h22i04bl